| P50 | author | Brian K Link | Q61054699 |
| | Bruce D. Cheson | Q88248387 |
| | Lawrence Baizer | Q113017187 |
| P2093 | author name string | Stephen M Ansell | |
| | John P Leonard | |
| | Brad S Kahl | |
| | Jonathan W Friedberg | |
| | Leo I Gordon | |
| | Paul M Barr | |
| | Nathan Fowler | |
| | Kami Maddocks | |
| | Richard F Little | |
| P2860 | cites work | Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry | Q27853195 |
| | Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive | Q28203197 |
| | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial | Q28286064 |
| | Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. | Q30370665 |
| | Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. | Q33503045 |
| | PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma | Q33690142 |
| | Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. | Q34156097 |
| | Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. | Q34646321 |
| | Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study | Q34663603 |
| | BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma | Q35004965 |
| | Pathogenesis of follicular lymphoma | Q36290288 |
| | Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience | Q37083964 |
| | Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource | Q37132380 |
| | Follicular lymphoma in the United States: first report of the national LymphoCare study | Q37334742 |
| | A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. | Q37412360 |
| | Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | Q37533656 |
| | Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and G | Q38056487 |
| | Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults | Q42597179 |
| | Follicular lymphoma grade 3B: is it a real disease? | Q43220044 |
| | Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial | Q44558622 |
| | The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). | Q44592953 |
| | High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial | Q44601131 |
| | CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma | Q45115068 |
| | Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study | Q46361336 |
| | Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma | Q46458338 |
| | Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al | Q46669969 |
| | Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. | Q53189779 |
| | Follicular lymphoma international prognostic index. | Q53289840 |
| | Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas | Q56992771 |
| | Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study | Q57515106 |
| | The natural history of initially untreated low-grade non-Hodgkin's lymphomas | Q70817025 |
| | Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma | Q73160379 |
| | Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project | Q77306442 |
| | Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3 | Q78033512 |
| | Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy | Q79782203 |
| | Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up | Q80361870 |
| | R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi | Q86491341 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2016-12-31 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Recommendations for Clinical Trial Development in Follicular Lymphoma | |
| P478 | volume | 109 | |